Feb 14 (Reuters) - The U.S. Food and Drug Administration (FDA) approved GSK's GSK.L combination vaccine to protect against meningococcal infection for use in individuals aged 10 through 25 years, the company said on Saturday.
(Reporting by Sneha S K, Mariam Sunny and Mrinmay Dey in Bengaluru; Editing by Alan Barona and Stephen Coates)
((Sneha.SK@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.